Novato-based BioMarin Pharmaceuticals said last night that it has acquired ZyStor Therapeutics, a biotech firm developing enzyme replacement therapies for treating lysosomal storage disorders. The deal is worth $22M upfront plus up to $93M based on future milestones. BioMarin said that ZyStor's lead product is current in investigational new drug (IND) application, with a clinical study expected to start in Q2 of 2011.